BR112020013405A2 - polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso - Google Patents

polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso Download PDF

Info

Publication number
BR112020013405A2
BR112020013405A2 BR112020013405-8A BR112020013405A BR112020013405A2 BR 112020013405 A2 BR112020013405 A2 BR 112020013405A2 BR 112020013405 A BR112020013405 A BR 112020013405A BR 112020013405 A2 BR112020013405 A2 BR 112020013405A2
Authority
BR
Brazil
Prior art keywords
seq
antigen
fact
poly
polymerosome
Prior art date
Application number
BR112020013405-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Madhavan Nallani
Fabien Decaillot
Thomas Andrew Cornell
Amit Kumar KHAN
Original Assignee
Acm Biolabs Pte Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acm Biolabs Pte Ltd. filed Critical Acm Biolabs Pte Ltd.
Publication of BR112020013405A2 publication Critical patent/BR112020013405A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112020013405-8A 2018-01-25 2019-01-25 polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso BR112020013405A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18153348.0 2018-01-25
EP18153348 2018-01-25
PCT/EP2019/051853 WO2019145475A2 (en) 2018-01-25 2019-01-25 Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof

Publications (1)

Publication Number Publication Date
BR112020013405A2 true BR112020013405A2 (pt) 2020-12-01

Family

ID=61192649

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020013405-8A BR112020013405A2 (pt) 2018-01-25 2019-01-25 polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso

Country Status (6)

Country Link
US (2) US12239736B2 (https=)
EP (1) EP3743101A2 (https=)
JP (2) JP7542257B2 (https=)
CN (1) CN111954541A (https=)
BR (1) BR112020013405A2 (https=)
WO (1) WO2019145475A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104936579B (zh) * 2012-11-19 2020-02-07 新加坡科技研究局 用于引发对免疫原的免疫响应的方法
BR112022001185A2 (pt) * 2019-08-01 2022-03-15 Acm Biolabs Pte Ltd Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
US11642407B2 (en) * 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
WO2021214339A2 (en) 2020-04-24 2021-10-28 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses
JP2024500360A (ja) * 2020-12-11 2024-01-09 エイシーエム バイオラブズ プライベート リミテッド 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法
CN117597109A (zh) * 2021-02-02 2024-02-23 Acm 生物实验室私人有限公司 聚合物囊泡相关联的佐剂用于刺激免疫应答的单独使用
AU2022258552A1 (en) * 2021-04-12 2023-10-19 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
CN113416788B (zh) * 2021-07-14 2022-04-29 兰州大学 一种与湖羊睾丸性状相关的adpgk基因分子标记及其应用
US20250295762A1 (en) * 2022-03-21 2025-09-25 The University Of North Carolina At Chapel Hill Composite bioactive compositions and applications thereof
WO2024081641A2 (en) * 2022-10-10 2024-04-18 Northwestern University Methods for preparing protein-conjugated nanocarriers
CN117045809B (zh) * 2023-09-27 2025-08-29 国家纳米科学中心 异种哺乳动物细胞来源的囊泡在制备疫苗载体中的应用
CN120860194A (zh) * 2025-07-15 2025-10-31 中国人民解放军总医院第一医学中心 一种流感病毒纳米疫苗及其制备方法与应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569825A (en) 1896-10-20 John h
US633425A (en) 1899-01-26 1899-09-19 Louis Henry Clyborne Wire-tightener.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
WO2005018610A1 (en) * 2003-08-21 2005-03-03 Lipotek Pty Ltd In vivo targeting of dendritic cells
AU2007319836A1 (en) * 2006-11-14 2008-05-22 The Trustees Of The University Of Pennsylvania Efficient nuclear delivery of antisense oligonucleotides
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
EP2601262A4 (en) * 2010-08-05 2014-01-22 Agency Science Tech & Res VESIGN STRUCTURE WITH SEVERAL CHAMBERS AND METHOD FOR THEIR EDUCATION
EP4218808A3 (en) 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvant and vaccine compositions
CN104936579B (zh) * 2012-11-19 2020-02-07 新加坡科技研究局 用于引发对免疫原的免疫响应的方法
US10017545B2 (en) * 2013-06-03 2018-07-10 University Of Maryland, College Park Compositions and vaccines comprising vesicles and methods of using the same
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
WO2016055611A1 (en) * 2014-10-09 2016-04-14 Universität Basel Self-assembled nanostructures and methods of use thereof
US9636397B2 (en) 2015-03-24 2017-05-02 VaxLiant, LLC Adjuvant compositions and related methods
CA3016457A1 (en) * 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy

Also Published As

Publication number Publication date
JP7542257B2 (ja) 2024-08-30
JP2024160341A (ja) 2024-11-13
CN111954541A (zh) 2020-11-17
WO2019145475A2 (en) 2019-08-01
US20210251899A1 (en) 2021-08-19
US20250186346A1 (en) 2025-06-12
JP2021512142A (ja) 2021-05-13
US12239736B2 (en) 2025-03-04
WO2019145475A3 (en) 2019-09-06
EP3743101A2 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
US20250186346A1 (en) Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
CN114502191B (zh) 通过施用具有关联的抗原的聚合物囊泡群和具有关联的佐剂的聚合物囊泡群来引发免疫应答的方法以及包含这两种聚合物囊泡群的组合物
CN110913903B (zh) 聚糖相互作用化合物和使用方法
CN110545847A (zh) 用于肿瘤的靶向免疫疗法的组合物和方法
JP2022552552A (ja) 活性薬剤または治療剤の送達のための水中油型エマルジョン製剤
CN112188887A (zh) 用于将活性剂和免疫调节剂靶向递送至淋巴结的方法和组合物
US20250281405A1 (en) Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
US20220105176A1 (en) Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
US20230398207A1 (en) Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
EP4288033B1 (en) Polymersome associated adjuvant for use in stimulating an immune response
Emam et al. Using PEGylated antigen-expressing extracellular vesicles to accomplish splenic B cell-targeted antigen delivery for induction of antibodies against SARS-CoV-2 spike protein
HK40092374A (zh) 聚糖相互作用化合物及使用方法

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]